SecBot SecBot
8-K ·Filed Nov 10, 2026

AZTR

Azitra, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed7d 7h ago SEC0001493152-26-050882
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor for initial first-in-human results of ATR-COSF by year-end 2026, which could provide the first clinical validation for the cosmetic program. Also track enrollment updates for the expanded ATR-04 Phase 1/2 trial, as patient recruitment into the new KRAS/MEK inhibitor cohorts will be a key catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

AZTR drug pipeline →

ATR-04

◆ Mixed Named in this 8-K
Impact
Phase
Phase 1/2
Time to market
Unknown — at least 3-5 years if Phase 1/2 data is positive, followed by Phase 3 trials and FDA review. The Fast Track designation could accelerate the timeline.
Next catalyst
None dated

What to watchWatch for ATR-04 Phase 1/2 first-cohort topline data expected Q4 2026, positive safety/efficacy signals could drive a sharp rally given the tiny market cap, but the ~6-month cash runway means a dilutive financing is likely before year-end regardless of results. The stock is a high-risk binary play on a single early-stage asset.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.6000
T+0 close · Nov 10, 2026 · via day close
Latest settled
−2.47%
T+1 · $0.5852
Vs SPY
−3.79%
α at T+1
Next horizon
T+5
due 9h ago
  1. T+0 · Nov 10 $0.6000entry
  2. T+1 · 6d ago −2.47%α −3.79% · $0.5852
  3. T+5 · due 9h ago Pending
  4. T+5 · todayOpen
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Azitra issued a press release announcing a presentation at BIO-Europe showing ex vivo data for ATR-COSF (a recombinant filaggrin protein cosmetic) with a 56% reduction in wrinkles from baseline, and an update on the ATR-04 Phase 1/2 trial expansion to include KRAS and MEK inhibitor patients. No financial data, guidance, or material corporate events were disclosed; the filing is a routine pipeline update.

Key Facts

  • Azitra will present at BIO-Europe on November 10, 2026, showing ATR-COSF ex vivo data: a 56% reduction in wrinkles from baseline in a human torso skin model.
  • ATR-COSF improved elasticity and wrinkle depth vs vehicle in ex vivo models at 48 hours.
  • Initial results from the first-in-human study of ATR-COSF are anticipated by year-end 2026.
  • The Phase 1/2 trial of ATR-04 was expanded in October 2026 to include patients with rashes due to KRAS and MEK inhibitors, and NF1 patients with MEK inhibitor-associated rash.
  • Approximately 85,000 patients undergo KRAS or MEK inhibitor treatment annually in the U.S., adding to the ~220,000 EGFR inhibitor patients.
  • No financial figures, guidance, or material agreements were disclosed in the filing.

Financial Impact

No financial impact stated; pre-clinical and early clinical pipeline update with no revenue or cost figures.

Risk Factors

  • Ex vivo results may not translate to human clinical outcomes; first-in-human study could fail or be delayed.
  • ATR-04 trial expansion adds complexity; enrollment in new cohorts may be slow or produce different safety/efficacy profiles.
  • Company has a $4M market cap and may need to raise additional capital to fund ongoing trials.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-050882
Exhibit: ex99-1.htm0001493152-26-050882
Document: 0001493152-26-050882-index-headers.html0001493152-26-050882
Document: 0001493152-26-050882-index.html0001493152-26-050882
Document: 0001493152-26-050882.txt0001493152-26-050882

Track record

16 reports on AZTR

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.73% at T+60 after the May 21, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13D Neutral 5/10 Entry $0.5805 Now $0.6090 +4.91% settles Feb 16
  2. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.6084 Now $0.6090 +0.10% settles Feb 11
  3. Nov 12, 20264d ago 8-K Neutral 4/10 No price data
  4. Nov 12, 20265d ago SC 13G/A Neutral 2/10 Entry $0.6685 Now $0.6090 −8.90% settles Feb 10
  5. Nov 10, 20267d ago 8-K Neutral 3/10 Viewing Entry $0.6000 Now $0.6090 +1.50% settles Feb 8
  6. Nov 10, 20267d ago Press Release Neutral 3/10 Entry $0.6000 Now $0.6090 +1.50% settles Feb 8
  7. Oct 29, 202619d ago 8-K Neutral 3/10 Entry $0.7571 Now $0.6090 −19.56% settles Jan 27
  8. Oct 26, 202622d ago 8-K Neutral 4/10 Entry $1.53 Now $0.6090 −60.20% settles Jan 22
  9. Oct 22, 202626d ago 8-K Neutral 3/10 Entry $0.0715 Now $0.6090 +751.75% settles Jan 21
  10. Oct 1, 20266w ago 8-K Neutral 4/10 Entry $0.1285 Now $0.6090 +373.93% settles Dec 28
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (17h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026